Archamps (France), December 19, 2018 at 7.00 am CET

Genkyotex announces an Extraordinary Shareholders' Meeting to be held on January 24, 2019 at 10 am and confirms the key development milestone for GKT831 in PBC

- ***Proposed reverse stock split***
- ***More than 50% of patients in the PBC study have completed the 24-week treatment period with GKT831***
- ***Final results of the study confirmed for spring 2019***

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, informs its shareholders that they are invited to attend an Extraordinary Shareholders' Meeting at 10 am on January 24, 2019 at Club Confair, 54 rue Laffitte, 75009 Paris, France to deliberate on a proposed reverse stock split.

This operation is part of Genkyotex's strategy to increase its visibility among investors in France and abroad. **This technical adjustment is purely arithmetical and has no impact on the value of Genkyotex shares held by the shareholders.**

The Company also confirms that the final results of the ongoing Phase II trial on GKT831 in patients with Primary Biliary Cholangitis will be published in the spring of 2019. To date, 66 of the 111 randomized patients have already completed the 24-week treatment period and 97 patients have completed 12 weeks of treatment. The safety profile remains good, as previously announced. There have been no treatment interruptions or early patient drop outs due to pruritus. The final results will include the data reported during the interim analysis and data pertaining to liver fibrosis and quality of life.

About Genkyotex

Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets. A leader in NOX therapies, its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.

Genkyotex's platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor is evaluated in a phase II clinical trial in primary biliary cholangitis (PBC, a fibrotic orphan disease) and in an investigator-initiated Phase II clinical trial in Type 1 Diabetes and Kidney Disease (DKD). A grant from the United States National Institutes of Health (NIH) of $8.9 million was awarded to Professor Victor Thannickal at the University of Alabama at Birmingham (UAB) to fund a multi-year research program evaluating the role of NOX enzymes in idiopathic pulmonary fibrosis (IPF), a chronic lung disease that results in fibrosis of the lungs, the core component of the program will be to conduct a Phase 2 trial with the GKT831 in patients with IPF. This product candidate may also be active in other fibrotic indications. Its second product candidate, GKT771, is a NOX1 inhibitor targeting multiple pathways in angiogenesis, pain processing, and inflammation, currently undergoing preclinical testing.

Genkyotex also has a versatile platform well-suited to the development of various immunotherapies (Vaxiclase). A partnership covering the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Private Ltd (Serum

Institute), the world's largest producer of vaccine doses, for the development by Serum Institute of cellular multivalent combination vaccines against a variety of infectious diseases. This partnership could generate approximately €150 million in future revenues for Genkyotex, before royalties on sales.

***For further information, please go to** www.genkyotex.com.*

GKTX
LISTED
EURONEXT

ELIGIBLE
PEA
PME

Disclaimer

This press release may contain forward-looking statements by the company with respect to its objectives. Such statements are based upon the current beliefs, estimates and expectations of Genkyotex's management and are subject to risks and uncertainties such as the company's ability to implement its chosen strategy, customer market trends, changes in technologies and in the company's competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release and actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include uncertainties involved in the development of Genkyotex's products, which may not succeed, or in the delivery of Genkyotex's products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affects Genkyotex's capacity to commercialize the products it develops. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the registration document (document de reference) registered by the French Markets Authority (the AMF) on 27 April 2018 under number R.18-037, and those linked to changes in economic conditions, the financial markets, or the markets on which Genkyotex is present. Genkyotex products are currently used for clinical trials only and are not otherwise available for distribution or sale.

INVESTORS	MEDIA	US
NewCap Dušan Orešanský, Tristan Roquet Montégon and Emmanuel Huynh +33 1 44 71 94 92 genkyotex@newcap.eu	**NewCap** Nicolas Merigeau, Arthur Rouillé +33 1 44 71 00 15 genkyotex@newcap.eu	**LifeSci Advisors, LLC** Brian Ritchie +1-212-915-2578 britchie@lifesciadvisors.com